Fibroblast growth factor receptor
FunctionFibroblast growth factor receptors (FGFR) are receptors which bind fibroblast growth factors (FGF). Each FGFR can activate several FGFs. Five FGFRs have been identified so far. FGFRs differ in their ligand specificity and tissue distribution. The binding of FGF to FGFR starts a cascade of signaling which influences mitogenesis and differentiation[1]. DiseaseMutation in FGFR3 causes achondroplasia[2] and is involved in myeloma[3]. Mutations in FGFR2 cause Crouzon syndrome[4]. Structural insightsFGFR consist of an extracellular ligand-binding domain (LBD), transmembrane helix domain and cytoplasmic tyrosine kinase activity domain (TKD) with phosphorylated tyrosine designated PTR. FGFR LBD contains 3 immunoglobulin-like domains D1, D2 and D3. (PDB code 1evt). 3D structures of fibroblast growth factor receptorFibroblast growth factor receptor 3D receptor
|
|
3D structures of fibroblast growth factor receptor3D structures of fibroblast growth factor receptor
Updated on 01-July-2019 {{#tree:id=OrganizedByTopic|openlevels=0|
- FGFR1
- FGFR1 tyrosine kinase domain residues 458-765
- 4uwy, 6mzq – hFGFR1 TKD - human
- 1fgk, 3kxx, 3ky2, 4rwi, 5flf – hFGFR1 TKD (mutant) - human
- 4wun, 5am6, 5ew8, 5o49, [[5o4a], 6mzw, 6c1o – hFGFR1 TKD + inhibitor
- 1agw, 1fgi, 2fgi, 3c4f, 3js2, 3rhx, 4f63, 4f64, 4f65, 3tt0, 4nk9, 4nka, 4nks, 5b7v, 5am7, 4rwj, 4rwk, 4rwl, 4uwb, 4uwc, 4zsa, 5uq0, 5vnd, 5ur1, 6p68, 6p69, 6c18, 6c19, 6c1b, 6c1c, 5z0s – hFGFR1 TKD (mutant) + inhibitor
- 5zv2 – hFGFR1 TKD (mutant) + anti-cancer drug
- 3krj – hFGFR1 TKD residues 538-678, 753-922 (mutant) + inhibitor
- 1xr0 – hFGFR1 residues 409-430 + FGFR signaling adaptor N terminal - NMR
- 3gqi – hFGFR1 TKD (mutant) with PTR + ACP
- 3gql – hFGFR1 TKD (mutant) + substrate
- 4uwy, 6mzq – hFGFR1 TKD - human
- FGFR1 ligand-binding domain D1 residues 35-208
- FGFR1 D1 complex with FGF
- 5w59 – hFGFR1 LBD D1 + FGF9
- 5w59 – hFGFR1 LBD D1 + FGF9
- FGFR1 D2,D3 residues 142-365 complex with FGF
- FGFR2
- FGFR2 tyrosine kinase domain
- 1gjo, 1oec, 2psq – hFGFR2 TKD
- 2pvy, 2pwl, 2py3, 2pz5, 2pzp, 2pzr, 2q0b, 4j95, 4j96, 4j97, 4j98, 4j99, 5ugx, 5uhn, 5ui0 – hFGFR2 TKD (mutant) + ACP
- 5ugl – hFGFR2 TKD (mutant) + ANP
- 3b2t – hFGFR2 TKD (mutant) + adenosine derivative
- 2pvf – hFGFR2 TKD with PTR + ACP + substrate peptide
- 3cly – hFGFR2 TKD (mutant) with PTR + ACP
- 5eg3 – hFGFR2 TKD (mutant) with PTR + ACP + phospholipase C γ
- 3ri1 – hFGFR2 TKD + inhibitor
- 1gjo, 1oec, 2psq – hFGFR2 TKD
- FGFR2 ligand-binding domain
- FGFR2 complex with FGF
- 1e0o – hFGFR2 (mutant) LBD D2,D3 + hFGF1 (mutant) + HS
- 3oj2, 3ojm – hFGFR2 (mutant) LBD D2,D3 + hFGF1
- 1djs – hFGFR2 LBD D2,D3 (mutant) + hFGF1
- 1ev2, 1ii4, 1iil – hFGFR2 LBD D2,D3 + hFGF2 (mutant)
- 4j23 – hFGFR2 LBD D2,D3 (mutant) + hFGF2 (mutant) + inhibitor
- 3cu1 – hFGFR2 LBD D2 + hFGF1
- 2fdb – hFGFR2 LBD D2,D3 + hFGF8b
- 1nun – hFGFR2 LBD D2,D3 + hFGF10
- 1e0o – hFGFR2 (mutant) LBD D2,D3 + hFGF1 (mutant) + HS
- FGFR3
- FGFR3 complex with FGF
- 1ry7 – hFGFR3 LBD + hFGF1
- 1ry7 – hFGFR3 LBD + hFGF1
- FGFR4
- FGFR4 tyrosine kinase domain
}}
ReferencesReferences
- ↑ Coutts JC, Gallagher JT. Receptors for fibroblast growth factors. Immunol Cell Biol. 1995 Dec;73(6):584-9. PMID:8713482 doi:http://dx.doi.org/10.1038/icb.1995.92
- ↑ Wilkin DJ, Szabo JK, Cameron R, Henderson S, Bellus GA, Mack ML, Kaitila I, Loughlin J, Munnich A, Sykes B, Bonaventure J, Francomano CA. Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome. Am J Hum Genet. 1998 Sep;63(3):711-6. PMID:9718331 doi:http://dx.doi.org/10.1086/302000
- ↑ Intini D, Baldini L, Fabris S, Lombardi L, Ciceri G, Maiolo AT, Neri A. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol. 2001 Aug;114(2):362-4. PMID:11529856
- ↑ Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995 Dec;11(4):462-4. PMID:7493034 doi:http://dx.doi.org/10.1038/ng1295-462